Nigel H. Russell

Guy's and St Thomas' NHS Foundation Trust — United Kingdom

Medicine · Health Sciences

78h-index24.0kcitations622works8.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(319), Hematopoietic Stem Cell Transplantation(167), Acute Lymphoblastic Leukemia research(127), Multiple Myeloma Research and Treatments(104), Chronic Myeloid Leukemia Treatments(104)

Publications620 total

Prognostic implications of myelodysplasia-related gene mutations in <i>NPM1</i>-mutated acute myeloid leukemia: a systematic review and meta-analysis
Haematologica·2026Open Access
Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences risk of acute myeloid leukemia
Blood·2026Open Access
All patients with acute myeloid leukemia and <i>FLT3</i>-ITD should be transplanted in first remission. Also in the era of tyrosine kinase inhibitors? – the CON
Haematologica·2026Open Access
CPX-351 versus daunorubicin, cytarabine plus gemtuzumab ozogamicin in older adults with non-adverse risk AML: NCRI AML18
Blood·2025Open Access
FLT3-ITD NGS-MRD refines risk stratification in NPM1 and FLT3 co-mutated AML beyond NPM1 PCR-MRD: Analysis of the UK NCRI AML17 and AML19 trials
Blood·2025Open Access
Validation of measurable residual disease as a surrogate endpoint in acute myeloid leukemia: A HARMONY Alliance study of European randomized trials
Blood·2025· 1 citedOpen Access
Diagnostic evaluation methods and prognostic impact of FLT3-ITD microclones in Acute Myeloid Leukemia (AML): A retrospective multicenter study on behalf of the EHA AML-specialized working group (SWG)
Blood·2025
Detection of KMT2A fusion transcripts after induction chemotherapy is strongly predictive of outcome in KMT2A rearranged AML: Results of an international collaborative study
Blood·2025Open Access
Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in <i>FLT3</i> -mutated AML
Blood Advances·2025· 1 citedOpen Access
Acute myeloid leukaemia cells express high levels of androgen receptor but do not depend on androgen signaling for survival
Leukemia·2025Open Access
Induction chemotherapy and molecular MRD influence outcomes in <i>KMT2A</i> -rearranged AML
Blood·2025
A pooled analysis of 3 large multicenter trials confirms a survival advantage for <i>NPM1</i> <sup>mut</sup> AML in MRD <sup>neg</sup> remission after intensive induction
HemaSphere·2025· 1 citedOpen Access
Multimodal and Data-Driven Assessment of Myeloid Neoplasms Refines Classification across Disease States
Blood Cancer Discovery·2025· 1 citedOpen Access
A revised prognostic model for patients with acute myeloid leukemia and first relapse
Blood Advances·2025Open Access
Molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI AML17 and AML19 randomised, controlled, phase 3 trials
The Lancet Haematology·2025· 7 citedOpen Access
Reply to: Treatment Intensification Based on Residual Disease in Elderly Patients With AML
Journal of Clinical Oncology·2025
Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial
Journal of Clinical Oncology·2025· 9 citedOpen Access
Fitness assessment in acute myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Blood Advances·2025· 17 citedOpen Access
Acute promyelocytic leukemia: long-term outcomes from the HARMONY project
Blood·2024· 28 cited
Eltrombopag Added to Standard Immunosuppressive Treatment Improves Long-Term Outcomes As Front-Line Therapy for Severe Aplastic Anemia: Final 2-Year Analysis of EBMT-Saawp Race Study
Blood·2024· 1 cited
page 1 of 31Next →

Frequent Co-authors

Alan K. Burnett(17), Robert K. Hills(16), Donald Milligan(9), Gordon Cook(8), Sylvie Freeman(7), Keith Wheatley(7), Charles Craddock(7), David Grimwade(6), Ann Hunter(6), Graham Jackson(6), Faith E. Davies(6), Gareth J. Morgan(6), Amanda Gilkes(5), Lars Kjeldsen(5), Jonathan Kell(5), Walter M. Gregory(5), Mark T. Drayson(5), Ann E. Hunter(5), John Yin(5), Mark J. Levis(4)